Document Detail


Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells.
MedLine Citation:
PMID:  20431887     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
PURPOSE: The milk thistle extract silymarin, alone or in combined chemotherapy, is now under investigation in anticancer research, with particular interest for its possible employ in the treatment of chemoresistant tumours. So far, the consequences of a silymarin pre-treatment have not been thoroughly investigated. We studied whether silymarin pre-treatment synergized with chemotherapy, exploring the dose-dependence of the interaction in sensitive and multidrug-resistant cells.
METHODS: We studied cell cycle perturbations induced by silymarin in two colon carcinoma cell lines, LoVo and the multidrug-resistant isogenic LoVo/DX. Synergism/additivity/antagonism of silymarin-doxorubicin silymarin-paclitaxel combined treatments were evaluated by isobologram/combination index analysis, in the whole spectrum of active and sub-active concentrations of all drugs. The mechanisms of silymarin interaction with the other drugs were investigated by measuring drug uptake and cell cycle perturbations.
RESULTS: Silymarin had similar antiproliferative activity against both cell lines. Pre-treatment with low silymarin concentrations synergised with both doxorubicin and paclitaxel in LoVo but not in LoVo/DX. Higher silymarin concentrations were additive with doxorubicin and paclitaxel in both cell lines. Silymarin favourably interfered with uptake and cell cycle effects of the chemotherapeutics in LoVo but not in LoVo/DX.
CONCLUSION: These findings confirm activity of silymarin against colon carcinoma, including multidrug-resistant types, at relatively high but clinically achievable concentrations. In view of its low toxicity, two schedules based on low- and high-dose silymarin pre-treatment might offer a valuable option for combined treatment.
Authors:
Valentina Colombo; Monica Lupi; Francesca Falcetta; Daniele Forestieri; Maurizio D'Incalci; Paolo Ubezio
Related Documents :
2178327 - Transformation renders mdr cells more sensitive to polyunsaturated fatty acids.
7587707 - Dyes providing increased sensitivity in flow-cytometric dye-efflux assays for multidrug...
16962737 - L1210 cells cultivated under the selection pressure of doxorubicin or vincristine expre...
7198507 - Continued expression of vinca alkaloid resistance by ccrf-cem cells after treatment wit...
2465827 - Cell sedimentation with gravity activation.
3855287 - Enhancement of the differentiation-inducing properties of 6-thioguanine by hypoxanthine...
Publication Detail:
Type:  Journal Article     Date:  2010-04-30
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  67     ISSN:  1432-0843     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  369-79     Citation Subset:  IM    
Affiliation:
Laboratory of Anticancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche "Mario Negri", Via La Masa 19, 20156, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of hemostatic durability between N-butyl cyanoacrylate and gelatin sponge particles in tr...
Next Document:  A reaction-diffusion malaria model with incubation period in the vector population.